ATE316571T1 - Purifikation von viruspräparaten - Google Patents

Purifikation von viruspräparaten

Info

Publication number: ATE316571T1
Authority: AT; Austria
Prior art keywords: purification; groups; virus preparations; polysacharide; sulfated
Prior art date: 1998-03-05

Application number

AT99937941T

Other languages

English (en)

Inventor

Michael Denis Johnston

Roderic Simon O'keeffe

Nigel Kenneth Harry Slater

Original Assignee

Cantab Pharmaceuticals Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-05

Filing date

1999-03-05

Publication date

2006-02-15

1999-03-05 Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd

2006-02-15 Application granted granted Critical

2006-02-15 Publication of ATE316571T1 publication Critical patent/ATE316571T1/de

Links

241000700605 Viruses Species 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
238000000746 purification Methods 0.000 title 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
229960000633 dextran sulfate Drugs 0.000 abstract 1
238000003306 harvesting Methods 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000012266 salt solution Substances 0.000 abstract 1
239000007790 solid phase Substances 0.000 abstract 1
241001529453 unidentified herpesvirus Species 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT99937941T 1998-03-05 1999-03-05 Purifikation von viruspräparaten ATE316571T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9804632.9A GB9804632D0 (en)	1998-03-05	1998-03-05	Virus preparations and methods

Publications (1)

Publication Number	Publication Date
ATE316571T1 true ATE316571T1 (de)	2006-02-15

Family

ID=10827994

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99937941T ATE316571T1 (de)	1998-03-05	1999-03-05	Purifikation von viruspräparaten

Country Status (13)

Country	Link
US (1)	US6267967B1 (de)
EP (1)	EP1062325B1 (de)
JP (1)	JP2002505101A (de)
AT (1)	ATE316571T1 (de)
AU (1)	AU3266599A (de)
BR (1)	BR9908424A (de)
CA (1)	CA2322615A1 (de)
DE (1)	DE69929612T2 (de)
DK (1)	DK1062325T3 (de)
ES (1)	ES2257867T3 (de)
GB (1)	GB9804632D0 (de)
PT (1)	PT1062325E (de)
WO (1)	WO1999045104A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783939B2 (en) *	2000-07-07	2004-08-31	Alphavax, Inc.	Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
ES2330202T5 (es) *	2001-09-06	2014-01-20	Alphavax, Inc.	Sistemas vectores basados en replicones de alfavirus
DE60327069D1 (de)	2002-04-30	2009-05-20	Oncolytics Biotech Inc	Verbesserte reinigungsmethode für viren
US20040208848A1 (en) *	2002-12-13	2004-10-21	Smith Jonathan F.	Multi-antigenic alphavirus replicon particles and methods
US7078218B2 (en) *	2002-12-13	2006-07-18	Alphavax, Inc.	Alphavirus particles and methods for preparation
US7442381B2 (en) *	2003-03-20	2008-10-28	Alphavax, Inc.	Alphavirus replicons and helper constructs
CA2503774C (en) *	2003-06-20	2007-09-25	Microbix Biosystems Inc.	Improvements in virus production
DE602004021260D1 (de) *	2003-07-11	2009-07-09	Alphavax Inc	Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
CN1989250B (zh)	2004-05-18	2013-11-20	阿尔法瓦克斯公司	Tc-83衍生的甲病毒属载体、颗粒和方法
ATE489965T1 (de) *	2004-09-09	2010-12-15	Novartis Vaccines & Diagnostic	Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
US7344839B2 (en) *	2004-12-23	2008-03-18	Aurx, Inc.	Virus preparations and methods
KR101397386B1 (ko) *	2005-12-13	2014-05-26	엑스테라 메디컬 코퍼레이션	혈액으로부터 병원성 미생물, 염증 세포 또는 염증단백질의 체외 제거를 위한 방법
JP2010526546A (ja)	2007-05-14	2010-08-05	バヴァリアン・ノルディック・アクティーゼルスカブ	ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
US8003363B2 (en) *	2007-05-14	2011-08-23	Bavarian Nordic A/S	Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US20080294361A1 (en) *	2007-05-24	2008-11-27	Popp Shane M	Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2008155683A1 (en)	2007-06-18	2008-12-24	Firmenich Sa	Malodor counteracting compositions and method for their use
US8460913B2 (en)	2007-06-21	2013-06-11	Alpha Vax, Inc.	Promoterless cassettes for expression of alpha virus structural proteins
CA2733399C (en) *	2008-08-11	2018-10-09	Sanofi Pasteur Biologics Co.	Compositions and methods for the production of alpha-herpesviruses
ES2861359T3 (es)	2009-12-01	2021-10-06	Exthera Medical Corp	Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
WO2012112724A1 (en)	2011-02-15	2012-08-23	Exthera Medical, Llc	Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
CA2829774C (en)	2011-03-14	2019-09-24	National Research Council Of Canada	Method of viral production in cells
EP3246400B1 (de) *	2012-01-09	2019-10-23	Sanofi Pasteur Biologics, LLC	Aufreinigung von herpesvirus
EP2852662B1 (de)	2012-05-21	2020-09-16	Sanofi Pasteur Limited	Herpesviruszusammensetzungen und zugehörige verfahren
EP2861273B1 (de)	2012-06-13	2017-08-23	ExThera Medical Corporation	Verwendung von heparin und kohlenhydraten zur behandlung von krebs
BR112015032134B1 (pt)	2013-06-24	2022-05-10	Exthera Medical Corporation	Método de ligação em ponto de extremidade de uma manose não redutora a um substrato e esfera possuindo uma manose ligada em ponto de extremidade
BR112016009827B1 (pt)	2013-11-08	2021-10-26	Exthera Medical Corporation	Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
EP3134146B1 (de)	2014-04-24	2024-12-25	ExThera Medical Corporation	Verfahren zur entfernung von bakterien aus blut unter verwendung einer hohen durchflussrate
US10857283B2 (en)	2014-09-22	2020-12-08	Exthera Medical Corporation	Wearable hemoperfusion device
US11911551B2 (en)	2016-03-02	2024-02-27	Exthera Medical Corporation	Method for treating drug intoxication
WO2017151797A1 (en)	2016-03-02	2017-09-08	Exthera Medical Corporation	Method for treating drug intoxication
WO2020231830A1 (en)	2019-05-16	2020-11-19	Exthera Medical Corporation	Method for modulating endothelial glycocalyx structure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE209738C (de)
JPS5341202B2 (de)	1974-03-12	1978-11-01
SE420977B (sv) *	1976-03-18	1981-11-16	Kabi Ab	Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
GB2080682B (en) *	1980-07-30	1984-03-28	Ciba Geigy Ag	Antiherpetically active lipstick
US4515714A (en) *	1983-03-09	1985-05-07	Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute	Method for purification of hepatitis B virus surface antigen
JPS6153226A (ja) *	1984-08-24	1986-03-17	Chemo Sero Therapeut Res Inst	単純ヘルペスサブユニツトワクチンの精製方法
US5024836A (en)	1987-05-04	1991-06-18	Merck & Co., Inc.	Stable lyophilized live herpes virus vaccine
DE69132311T2 (de)	1990-09-25	2000-12-14	Cantab Pharmaceuticals Research Ltd., Cambridge	Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
JPH06234659A (ja)	1992-05-05	1994-08-23	Handai Biseibutsubiyou Kenkyukai	安定化生ワクチン
CA2097019C (en)	1992-06-04	2007-07-24	Philip J. Provost	Process for attenuated varicella zoster virus vaccine production
US5360736A (en)	1992-06-04	1994-11-01	Merck & Co., Inc.	Process for attenuated varicella zoster virus vaccine production
JPH08507784A (ja)	1993-03-19	1996-08-20	キャンタブファーマシューティカルズリサーチリミティド	ウイルス・ワクチン
US5447859A (en) *	1993-07-16	1995-09-05	Viagene	Method for the purification or removal of retroviruses using sulfated cellulose

1998
- 1998-03-05 GB GBGB9804632.9A patent/GB9804632D0/en not_active Ceased
1999
- 1999-03-05 EP EP99937941A patent/EP1062325B1/de not_active Expired - Lifetime
- 1999-03-05 JP JP2000534636A patent/JP2002505101A/ja active Pending
- 1999-03-05 AT AT99937941T patent/ATE316571T1/de not_active IP Right Cessation
- 1999-03-05 AU AU32665/99A patent/AU3266599A/en not_active Abandoned
- 1999-03-05 ES ES99937941T patent/ES2257867T3/es not_active Expired - Lifetime
- 1999-03-05 BR BR9908424-4A patent/BR9908424A/pt not_active Application Discontinuation
- 1999-03-05 CA CA002322615A patent/CA2322615A1/en not_active Abandoned
- 1999-03-05 DE DE69929612T patent/DE69929612T2/de not_active Expired - Lifetime
- 1999-03-05 PT PT99937941T patent/PT1062325E/pt unknown
- 1999-03-05 DK DK99937941T patent/DK1062325T3/da active
- 1999-03-05 WO PCT/GB1999/000669 patent/WO1999045104A2/en not_active Ceased
- 1999-03-05 US US09/263,140 patent/US6267967B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69929612T2 (de)	2006-11-02
ES2257867T3 (es)	2006-08-01
GB9804632D0 (en)	1998-04-29
WO1999045104A3 (en)	1999-11-04
DE69929612D1 (de)	2006-04-13
CA2322615A1 (en)	1999-09-10
DK1062325T3 (da)	2006-05-15
EP1062325B1 (de)	2006-01-25
EP1062325A2 (de)	2000-12-27
BR9908424A (pt)	2000-10-31
WO1999045104A2 (en)	1999-09-10
AU3266599A (en)	1999-09-20
PT1062325E (pt)	2006-05-31
US6267967B1 (en)	2001-07-31
JP2002505101A (ja)	2002-02-19

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1062325

Country of ref document: EP

2011-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69929612D1 (de)	2006-04-13	Purifikation von viruspräparaten
Bridgen et al.	1977	Human lymphoblastoid interferon. Large scale production and partial purification.
RU94046367A (ru)	1997-03-27	Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
AU4052389A (en)	1990-03-05	Derivatized glass supports for peptide and protein sequencing
AU7489687A (en)	1988-01-11	Translation of mrna
EP0670369A3 (de)	1998-09-02	An menschliches programmiertes Zelltod relatiertes Peptid, und dessen kodierende DNA
ATE188740T1 (de)	2000-01-15	Viruspartikel mit veraendertem wirtspektrum
ES2183133T3 (es)	2003-03-16	Composiciones de lipidos.
CA2169834A1 (en)	1995-03-02	Pharmaceutical formulations of nerve growth factor
BR9711457A (pt)	2000-01-18	Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
FR2738151B1 (fr)	1997-09-26	Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
NL300249I1 (nl)	2007-02-01	Cefalosporinen en homologen, bereidingen en farmaceutische preparaten.
RS51512B (sr)	2011-06-30	Postupak za prečišćavanje interferonskih proteina pomoću katjonske izmenjivačke hromatografije
EP0754229A1 (de)	1997-01-22	Afamin: ein menschliches serum albumin ähnliches protein
ATE130198T1 (de)	1995-12-15	Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
FI72143C (fi)	1987-04-13	Foerfarande foer framstaellning av maenniskointerferon.
AU6745287A (en)	1987-07-16	Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
TR199900661T2 (xx)	1999-06-21	Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DE3884680D1 (de)	1993-11-11	Äusseres Membranprotein F von Pseudomonas aeruginosa.
DE69940692D1 (de)	2009-05-20	Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
EP0373540A3 (de)	1991-10-02	Verfahren zur Reinigung des Fibroblast-Wachstumsfaktor-Proteins
EP0676413A3 (de)	1996-04-03	Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
KR930004326A (ko)	1993-03-22	콘드로모듈린-ii 단백질
DE59107762D1 (de)	1996-06-05	Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren
AU2459188A (en)	1989-05-04	Anticoagulative protein pp4-x, and its preparation and use